---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-065899"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:38:06.360296+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma shareholders approve stock plan increase and report Phase 3 trial enrollment progress

## Summary
- Shareholders approved amendment to 2015 Stock Plan, increasing shares reserved by 3,000,000 to 10,713,670.
- Svetlana Lucas and Sanjay Shukla elected as Class III directors with majority votes.
- Ratification of Ernst & Young as independent auditor for FY2024 (54.5M for, 327K against).
- Advisory approval of executive compensation (42.5M for, 398K against).
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipates completing enrollment in Q2 2024; final patient dosing may occur in July 2024.

## SEC filing metadata
- accession: 0000950170-24-065899
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 5.07, 5.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017024065899/0000950170-24-065899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017024065899/life-20240522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-065899
- JSON: https://secwatch.observer/filing/0000950170-24-065899.json
- Plain text: https://secwatch.observer/filing/0000950170-24-065899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.